Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Oakmark Global Fund David G. Herro, Tony Coniaris, Eric Liu, M. Colin Hudson, John A. Sitarz | “Cooper Companies is a U.S.-headquartered medical device company that manufactures contact lenses and women's health products. The contact lens industry benefits from an oligopolistic market structure with significant barriers to entry, highly recurring revenue streams, and historically had consistently positive pricing dynamics that support mid-single-digit market growth over time. Cooper has an impressive track record of contact lens market share gains, which we attribute to its leading position in specialty lenses and its unique private-label strategy. We are encouraged by recent steps taken to improve free cash flow conversion, reaccelerate growth, and optimize the product portfolio. The stock has pulled back sharply alongside the broader medical technology sector and now trades at a meaningful discount to public peers, private market transactions, and its own trading history. We were pleased to initiate a position at what we view as an attractive entry point relative to our estimate of intrinsic value.” | NEUTRAL | Q2 2026 Jul 15, 2026 | View Pitch |
Diamond Hill Large Cap Strategy Austin Hawley | “Medical device manufacturer Cooper Companies is a global leader in contact lenses and women's health and fertility care. We initiated a position as revenue growth deceleration and transitory execution challenges weighed on valuation. Long term, growth in the contact lens industry is expected to remain healthy. The company is positioned to gain modest market share. Investments in women's health should pay off as cyclical headwinds ease. BSD Analysis: Cooper is a quiet medtech compounder built on vision correction and women's health, two categories driven by demographics rather than cycles. Contact lenses behave like consumables once patients are fitted, creating recurring revenue that doesn't show up in headline growth debates. Investors worry about competition and miss how sticky practitioner relationships really are. In women's health, regulatory barriers protect incumbents more than they slow them. Margins expand through mix and scale, not blockbuster innovation. Execution consistency matters more than flash here. This is healthcare demand hiding inside a “boring” device company.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Cambiar SMID Fund Ania A. Aldrich | “One representative purchase in the quarter was The Cooper Companies (COO). Cooper Companies is a medical device company, deriving ~65% of revenues from contact lenses and the balance from women's health products. A favorable aspect of Cooper's lenses business is that the average contact wearer is brand loyal for seven years, which gives the company a predictable cadence of revenues. Sales have slowed in recent quarters due to capacity constraints of Cooper's MyDay disposable lenses. The expansion in capacity (now complete) also hampered free cashflow. Our investment thesis is primarily based on the anticipated reacceleration of growth in the lens business, which should provide a catalyst for an upward re-rating in valuation. An additional positive (although not necessary) would be a potential split of the company's vision and women's health businesses. BSD Analysis: Cooper's moat is niche dominance in medical devices where switching costs are clinical, not contractual. CooperVision benefits from practitioner trust and patient habituation—once a lens works, nobody experiments casually. Recurring consumables drive predictable revenue, even if growth optics look unexciting. Pricing power exists, but it's incremental and disciplined rather than aggressive. The women's health business adds diversification, though returns there are lumpier and more execution-dependent. Innovation cadence matters because eye care quietly commoditizes if you stand still. Currency and emerging-market exposure add noise without changing the thesis. The bull case is steady global vision correction demand with operating leverage. Cooper compounds by being boring, trusted, and very hard to replace.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Kovitz Core Equity Kovitz Investment Group Partners, LLC | “Our investment in Cooper Companies builds our exposure to the vision care industry alongside our investment in Alcon. Like Alcon, Cooper is a leading manufacturer of contact lenses, an industry characterized by an oligopolistic structure with strong barriers to entry. The company has achieved consistent market share gains over the last 15+ years aided by its unique ability to offer both private label and branded contacts to large retailers. Recent share price weakness driven by transitory issues in the contact lens business created an attractive opportunity to initiate a position. BSD Analysis: Cooper's entrenched market share, improving cash flow post-investment cycle, and defensive health care exposure present a strong total-return setup. Trading at a discount to historical averages with leverage declining, margin expansion and steady demand recovery should catalyze rerating.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Diamond Hill Small Cap Fund Aaron Monroe | “Shares of mortgage servicing company Mr. Cooper Group rose as its acquisition by Rocket Companies closed as the quarter concluded. Investor sentiment has also been buoyed by the Fed's recent rate cut, which should give a boost to housing and refinancing demand in the period ahead. BSD Analysis: The Rocket merger provides scale and cost synergies, strengthening Cooper's market position in mortgage servicing. Lower interest rates will likely expand refinancing volumes and drive higher prepayment income. With a strong balance sheet and improving ROE, Mr. Cooper remains well-positioned for sustained earnings growth.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “The Cooper Companies, Inc. is a medical technology firm with two main divisions: CooperVision, a leader in contact lenses, and CooperSurgical, which focuses on women's health, including reproductive care and fertility. Despite strong quarterly performance and a full-year guidance raise, the stock fell on slightly lowered growth forecasts for the contact lens industry. While still growing faster than the industry, the lower guidance brought a punitive response from investors, a recurring theme for healthcare companies. We maintain confidence in the company's fundamentals and long-term growth potential, and slightly trimmed our position. BSD Analysis: Cooper remains a high-quality compounder with leadership in the global contact lens market and exposure to secular fertility trends. Near-term sentiment weakness reflects modestly reduced market growth expectations rather than deterioration in fundamentals. Shares trade at a discount to historical P/E multiples, offering upside as industry growth normalizes. Catalysts include product launches, margin expansion within CooperSurgical, and stabilization of contact lens demand.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
